SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

AXSM

Axsome Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed14d 18h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong revenue beat and narrowing losses support the company's path to profitability. Key catalysts ahead include the AXS-12 PDUFA decision in May 2027 and multiple Phase 3 readouts in 2027. Monitor prescription trends and payer coverage updates for continued commercial momentum.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

AXSM drug pipeline →

AXS-12

● Neutral Named in this press release
Impact
Phase
Filed/PDUFA (NDA accepted; Phase 3 completed)
Time to market
NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
Next catalyst
PDUFA date · May 1, 2027 165d

What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$136.01
T+0 close · Nov 2, 2026 · via day close
Latest settled
−1.51%
T+5 · $133.96 · next T+20 in 14d
Vs SPY
−1.59%
α at T+5
Latest observation
+3.05%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $136.01entry
  2. T+1 · 14d ago +2.65%α +2.35% · $139.61
  3. T+5 · 8d ago −1.51%α −1.59% · $133.96
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome Therapeutics reported Q3 2026 net product revenue of $259.7M, 52% YoY growth, beating the $249.2M consensus. Net loss narrowed to $12.9M ($0.25 per share) from $47.2M ($0.94 per share) a year ago, significantly better than the consensus EPS loss of $0.64. The company highlighted strong Auvelity and Sunosi prescription trends and initiated the Phase 3 SUMMIT trial for AXS-05 in smoking cessation.

Key Financial Metrics

EPS
−$0.25
est −$0.64 · +60.9%
Revenue
$259.7M
est $249.2M · +4.2% · +51.9% YoY
Rating
beat

Key Facts

  • Q3 2026 total net product revenue $259.7M, up 52% YoY from $171.0M, above consensus $249.2M.
  • Net loss $12.9M ($0.25 per share) vs $47.2M ($0.94 per share) YoY, beating consensus EPS loss of $0.64.
  • Auvelity net product sales $207.6M, up 53% YoY; total prescriptions ~302,000, up 40% YoY.
  • Sunosi net product revenue $48.2M, up 47% YoY; prescriptions up 15% YoY.
  • Symbravo net product sales $3.9M, up 88% YoY; prescriptions up 382% YoY.
  • Cash and equivalents $313.9M at Sep 30, 2026; company believes cash sufficient to fund operations into cash flow positivity.
  • Phase 3 SUMMIT trial of AXS-05 for smoking cessation initiated; topline results expected 2H 2027.
  • AXS-12 NDA for narcolepsy/cataplexy under FDA review with PDUFA date May 1, 2027.

Financial Impact

Revenue beat consensus by $10.5M (4.2%); EPS beat consensus by $0.39 (60.9%); net loss narrowed significantly YoY.

revenueepsnet losscash position

Segment Breakdown

SegmentRevenueGrowth
AUVELITY$207.6M+52.5%
SUNOSI$48.2M+47.0%
SYMBRAVO$3.9M+85.7%

Risk Factors

  • Company remains unprofitable with accumulated deficit of $1.43B; path to cash flow positivity depends on sustained revenue growth.
  • SG&A expenses rose 35% YoY to $203.1M, outpacing revenue growth; operating leverage not yet demonstrated.
  • Pipeline programs are early-stage; regulatory and clinical trial risks for AXS-12, AXS-05, and solriamfetol candidates.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3392981

Track record

26 reports on AXSM

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Viewing Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 7h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026